Taking linaclotide are not defecation, indicating that the patient’s disease is not in the therapeutic scope of linaclotide. Linaclotide is a guanylate cyclooxygenase agonist, which can bind with the corresponding receptor on the epithelial surface of the small intestine, promote the secretion of intestinal fluid in the intestinal lumen, accelerate intestinal peristalsis, and achieve the effect of promoting defecation, which can treat constipation-type irritable bowel syndrome. If the constipation is caused by intestinal space-occupying lesions, congenital megacolon, etc., the manifestation of not having a bowel movement even after taking linaclotide can occur, which indicates that the patient’s disease is not within the scope of treatment of this drug. Common adverse reactions when using linaclotide are dizziness, headache; pregnant and lactating women should not apply the drug; the drug is prohibited for those who are allergic to linaclotide. If the patient has the need to use the drug, it must be carried out under the guidance of a professional physician, and the treatment program should be adjusted under the guidance of the physician when the treatment effect is not satisfactory.